Source-grounded facts extracted from AGENUS INC's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Austin Charette resigned as Principal Accounting Officer at AGENUS INC.
“On May 12, 2026, Austin Charette, Senior Director, Financial Reporting and Compliance and Principal Accounting Officer of Agenus Inc. (the "Company"), informed the Company he will be resigning effective May 29, 2026.”
AGENUS INC reported financial results for the full year ended December 31, 2025.
“On March 16, 2026, Agenus Inc. announced its financial results for the quarter and year ended December 31, 2025.”
AGENUS INC reported financial results for the fourth quarter ended December 31, 2025.
“On March 16, 2026, Agenus Inc. announced its financial results for the quarter and year ended December 31, 2025.”
AGENUS INC issued 2,133,333 shares of common stock to Zynext Ventures USA LLC for $16.0 million ($7.50/share).
“Agreement (the “SPA”), pursuant to which Zynext agreed to purchase 2,133,333 shares of the Company’s common stock (the “Shares”) for an aggregate purchase price of approximately $16.0 million, or $7.50 per share. On January 15, 2026, the transactions contemplated by the SPA closed. The foregoing description of the SPA does not purport to be complete and is qualified”
AGENUS INC completed a disposition involving Zydus Pharmaceuticals (USA) Inc. (subsequently assigned to Zydilac Bio, LLC) for $75.0 million (closed 2026-01-15).
“On January 15, 2026, the transactions contemplated by the Purchase Agreement closed. Pursuant to the Purchase Agreement, on January 15, 2026, Agenus received consideration of $75.0 million, less certain reimbursable expenses and other required closing payments. The disposition of the Purchased Assets constituted a significant business disposition for the purposes”
AGENUS INC amended Amendment Agreement with Ligand Pharmaceuticals Incorporated (effective 2026-01-03).
“On January 3, 2026, Agenus Inc. (the “Company”), Agenus Royalty Fund, LLC and Agenus Holdings 2024, LLC entered into an amendment and release agreement (the “Amendment Agreement”) with Ligand Pharmaceuticals Incorporated (“Ligand”) related to a Purchase and Sale Agreement and related Warrant each previously disclosed in the Company’s Current Report on Form 8-K filed with the SEC on May 7, 2024.”
AGENUS INC incurred loan of up to $10,000,000 with Zydus Pharmaceuticals (USA) Inc. at 3.81% per annum maturing matures upon the closing of the Asset Purchase Agreement and Securities Purchase Agreement signed by Agenus and Zydus on June 3, 2025, or, if such closings will.
“On October 8, 2025, Agenus Inc. (“Agenus”) entered into a Promissory Note Agreement (the “Note”) with Zydus Pharmaceuticals (USA) Inc. (“Zydus”), a wholly owned subsidiary of Zydus Lifesciences Limited, for up to $10,000,000 (the “Principal Amount”). The Note bears interest at 3.81% per annum and matures upon the closing of the Asset Purchase Agreement and Securities Purchase Agreement signed by Agenus and Zydus on June 3, 2025 (together, the “APA/SPA”), or, if such closings will not occur, within 10 days after notification that the APA/SPA closings will not be consummated.”
AGENUS INC amended senior notes of $10.5 million at increased from 8% to 9% per annum maturing July 20, 2026.
“extended the maturity date of $10.5 million of senior subordinated promissory notes previously issued in 2015 (the “2015 Notes”) by sixteen months from February 20, 2025 to July 20, 2026; • increased the interest rate under the 2015 Notes from 8% to 9% per annum”
AGENUS INC announced a restructuring with charges of approximately $1.1 million affecting Agenus Inc. (excluding its independently operating subsidiaries) (reducing its workforce).
“Costs associated with the workforce reduction are primarily severance payments and are estimated at approximately $1.1 million.”
Ulf Wiinberg resigned as Director at AGENUS INC.
“On October 30, 2024, Ulf Wiinberg resigned as a director at Agenus Inc. (the “Company”), effective as of 5:00 p.m. Eastern Time on November 5, 2024.”
Thomas L. Harrison was elected as Class III director at AGENUS INC.
“On August 7, 2024, the Board of Directors (the “Board”) of Agenus elected Thomas L. Harrison to become a Class III director of Agenus with an initial term that expires at Agenus’s annual meeting of stockholders in 2027.”
Jennifer Buell was appointed as Director at AGENUS INC.
“Dr. Jennifer Buell was appointed to the Board of Directors of Agenus Inc. (Agenus) on June 11, 2024, effective immediately.”
AGENUS INC completed a disposition involving Ligand Pharmaceuticals Incorporated for $75 million (closed 2024-05-29).
“On May 29, 2024, the transactions contemplated by the Purchase Agreement closed. Pursuant to the Purchase Agreement, on May 30, 2024, Agenus received consideration of $75 million, less certain reimbursable expenses upon the completion of the sale to Ligand of the following assets: (i) 31.875% of the development, regulatory and commercial milestone”
AGENUS INC reported financial results for the quarter ended March 31, 2024.
“On May 7, 2024, Agenus Inc. announced its financial results for the quarter ended March 31, 2024. In connection with the announcement, the Company issued a press release, which is being furnished as Exhibit 99.1 to this current report on Form 8-K.”
AGENUS INC entered into Purchase Agreement with Ligand Pharmaceuticals Incorporated valued at $75 million (effective 2024-05-06).
“On May 6, 2024, Agenus Inc. (the “Company”), Agenus Royalty Fund, LLC and Agenus Holdings 2024, LLC entered into a Purchase and Sale Agreement (the “Purchase Agreement”) with Ligand Pharmaceuticals Incorporated (“Ligand”) for the sale to Ligand of the following (the “Purchased Assets”)”
AGENUS INC: Certificate of Eighth Amendment to effect a 1-for-20 reverse stock split of common stock (effective 2024-04-12).
“On April 4, 2024, Agenus Inc. (the “Company”) filed a Certificate of Eighth Amendment (the “Certificate of Amendment”) to its Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) with the Secretary of State of the State of Delaware to effect a reverse stock split of the Company’s issued and outstanding common stock, par value $0.01 (the “Common Stock”) at a ratio of 1-for-20 (the “Reverse Stock Split”).”
AGENUS INC shareholders approved Approval of the Certificate of Amendment to the Certificate of Incorporation to effect a reverse stock split of the Company’s issued and outstanding common stock at a ratio of 1-for-20 at the 2024-04-03 meeting.
“The final voting results of the Special Meeting are as follows: Proposal 1 : Approval of the Certificate of Amendment to the Certificate of Incorporation to effect a reverse stock split of the Company’s issued and outstanding common stock at a ratio of 1-for-20. In accordance with the results below, Proposal 1 was approved. For Against Abstaining Broker Non-Votes 230,562,224 58,628,037 470,982 0”
AGENUS INC reported year ended December 31, 2023 results: revenue $156 million, net income -$257 million, EPS -$0.69 per share.
“For the year ended December 31, 2023, we recognized revenue of $156 million and incurred a net loss of $257 million, or $0.69 per share.”
AGENUS INC received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
“December 4, 2023, Agenus Inc. (the “Company") was notified by the Nasdaq Stock Market's Listing Qualifications Department that the Company’s common stock's closing bid price had not met the $1.00 minimum bid price requirement for 31 consecutive business days, as required by Nasdaq Listing Rule 5550(a)(2). This situation, however, will not impact the listing of the Company's common stock on the Nasdaq Capital Market for a minimum of 180 days with the possibility of an extension of another 180 days. The Company has been granted an initial automatic 180-day period, ending on June 3, 2024, to rect”
AGENUS INC reported financial results for the third quarter 2023.
“On November 7, 2023, Agenus Inc. announced its financial results for the quarter ended September 30, 2023.”
AGENUS INC announced a restructuring with charges of approximately $1.4 million affecting Agenus Inc. (excluding its independently operating subsidiaries) (approximately 25%).
“As part of this effort, Agenus Inc. (excluding its independently operating subsidiaries) is reducing its workforce by approximately 25%, which the company expects to result in savings of approximately $2.8 million by year-end, after accounting for the cost of the workforce reduction of approximately $1.4 million.”
AGENUS INC shareholders approved Non-binding advisory vote on frequency of future advisory votes on executive compensation at the 2023-06-12 meeting.
“For Proposal 5, the Company’s stockholders recommended future advisory votes on the compensation of the Company’s named executive officers annually. The votes cast at the Annual Meeting were as follows: 1 Year 2 Years 3 Years Abstain Broker Non-Votes 144,789,017 1,248,664 53,203,682 5,075,670 48,721,597”
AGENUS INC shareholders approved Ratify appointment of KPMG LLP as independent registered public accounting firm for fiscal year 2023 at the 2023-06-12 meeting.
“The Company’s stockholders approved Proposal 4. The votes cast at the Annual Meeting were as follows: For Against Abstain Broker Non-Votes 245,143,313 5,803,615 2,091,882 N/A”
AGENUS INC shareholders approved Non-binding advisory vote on compensation of named executive officers at the 2023-06-12 meeting.
“The Company’s stockholders approved Proposal 3. The votes cast at the Annual Meeting were as follows: For Against Abstain Broker Non-Votes 181,293,807 19,195,313 3,828,093 48,721,597”
AGENUS INC shareholders approved Approve amendment to Company’s 2019 Employee Stock Purchase Plan to increase shares from 1,000,000 to 2,000,000 at the 2023-06-12 meeting.
“The Company’s stockholders approved Proposal 2. The votes cast at the Annual Meeting were as follows: For Against Abstain Broker Non-Votes 189,724,965 13,716,185 876,063 48,721,597”
AGENUS INC shareholders approved Election of Garo H. Armen, Susan Hirsch, and Ulf Wiinberg as Class II directors at the 2023-06-12 meeting.
“The Company’s stockholders approved the Class II director nominees recommended for election in Proposal 1 at the Annual Meeting. The Company’s stockholders voted for the Class II directors as follows: Class I Director Nominees For Against Withheld Broker Non-Votes Garo H. Armen 192,604,048 0 11,713,165 48,721,597 Susan Hirsch 193,910,825 0 10,406,388 48,721,597 Ulf Wiinberg 190,912,519 0 13,404,694 48,721,597”
AGENUS INC reported the first quarter ended March 31, 2023 results: revenue $22.9 million, net income $70.9 million, EPS $0.22 per share.
“For the first quarter ended March 31, 2023, we recognized revenue of $22.9 million and incurred a net loss of $70.9 million (including non-cash expenses of $24.9 million) or $0.22 per share.”
AGENUS INC reported financial results for quarter and year ended December 31, 2022.
“On March 14, 2023, Agenus Inc. announced its financial results for the quarter and year ended December 31, 2022.”
Wadih Jordan resigned as Director at AGENUS INC.
“On December 21, 2022, Wadih Jordan sent notice of his resignation as a director at Agenus Inc. (the "Company"), effective as of December 31, 2022.”
AGENUS INC amended senior notes of $13.0 million with existing noteholders maturing February 20, 2025.
“On November 30, 2022, Agenus Inc. (the “Company”) entered into an Amendment to Notes, Termination of Warrants and Sale of New Warrants (the “Amendment”) with existing noteholders, pursuant to which the Company: • extended the maturity date of the $13.0 million senior subordinated promissory notes previously issued by the Company to such noteholders in 2015 (the “2015 Notes”) by two years from February 20, 2023 to February 20, 2025;”
AGENUS INC amended Amendment to Notes, Termination of Warrants and Sale of New Warrants with existing noteholders valued at $13.0 million (effective 2022-11-30).
“On November 30, 2022, Agenus Inc. (the “Company”) entered into an Amendment to Notes, Termination of Warrants and Sale of New Warrants (the “Amendment”) with existing noteholders, pursuant to which the Company: • extended the maturity date of the $13.0 million senior subordinated promissory notes previously issued by the Company to such noteholders in 2015 (the “2015 Notes”) by two years from February 20, 2023 to February 20, 2025; • terminated the warrants held by such noteholders to purchase 1,300,000 shares of the Company’s common stock previously issued in 2015; • terminated the warrants held by such noteholders to purchase 650,000 shares of the Company’s common stock previously issued in 2020; and • issued to such noteholders new warrants to purchase 1,300,000 shares of the Company’s common stock that will expire February 20, 2026 and issued new warrants to purchase 650,000 shares of the Company’s common stock that will expire February 20, 2028, all such warrants having an exercis”
AGENUS INC reported the third quarter of 2022 results: revenue $22.8 million, net income $56.7 million, EPS $0.19 per share.
“We recognized revenue of $22.8 million and incurred a net loss of $56.7 million, or $0.19 per share, for the third quarter ended September 30, 2022.”
Jennifer Buell resigned as President and Chief Operating Officer at AGENUS INC.
“Effective December 31, 2021, Dr. Jennifer Buell resigned as Agenus Inc.’s (the “Company”) President and Chief Operating Officer to become the President and Chief Executive Officer of MiNK Therapeutics, Inc. (“MiNK”), a subsidiary of the Company.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.